Nimotuzumab Plus Tislelizumab for Recurrent and Metastatic Cervical Cancer
Clinical trial NCT06039891 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06039891
- Sponsor
- Peking Union Medical College Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-10-01
- Primary completion
- 2024-10-01
- Enrollment
- 55
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.